Dual PI3K and HDAC inhibitor, CUDC-907, effectively inhibits endometrial cancer growth in vitro and in vivo
Our findings suggest that CUDC-907 is a promising agent that can re-sensitize tumors to progestin therapy and improve outcomes for EC patients. This study supports CUDC-907 as a potent treatment strategy in endometrial cancer and identifies IGF-1 as a potential surrogate serum biomarker for therapeutic response.
Authors
- Shujie Yang (ORCID: https://orcid.org/0000-0003-1753-3068)
- Yumi Imai (ORCID: https://orcid.org/0000-0001-5046-4223)
- Vanessa J Lazaro-Camp
- Wendy Meng
- Sharon L. Gardner (ORCID: https://orcid.org/0000-0002-8857-5487)
- Tianyue Li (ORCID: https://orcid.org/0000-0001-7682-7483)
- Mariah Leidinger (ORCID: https://orcid.org/0009-0001-6469-334X)
- Amanda Qi
- M Meehan
- Lillie Lamont
- Liangyun Lan (ORCID: https://orcid.org/0000-0002-2656-6059)
- Xudong Zhang (ORCID: https://orcid.org/0000-0002-5157-4544)
- Xiangbing Meng (ORCID: https://orcid.org/0000-0002-9612-6438)
- Lu Zhao (ORCID: https://orcid.org/0000-0002-1210-5403)
- Yan Xiong (ORCID: https://orcid.org/0000-0001-5507-6991)
Institutions
- University of Iowa (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-04
- DOI
- https://doi.org/10.3389/fonc.2025.1531805
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00